The Canadian guide on tumours with potential NTRK fusions recommends testing for androgen receptors and HER-2 in ductal carcinomas and NOS adenocarcinomas and, if negative, testing for NTRK (Table 4) [59]. Here, AR is linked to breast ductal adenocarcinoma.